Brett Hughes COSA 2015 ASM

Abstracts this author is presenting:

• Efficacy and safety of lenvatinib for the treatment of patients with ¹³¹I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy — Posters 2
• Effect of age and lenvatinib treatment on overall survival for patients with ¹³¹I-refractory differentiated thyroid cancer in SELECT — Posters 2
• Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in ¹³¹I-refractory differentiated thyroid cancer (SELECT). — Posters 2